论文部分内容阅读
目的 探讨应用 β 受体阻滞剂对介入治疗后血清肌酸磷酸激酶的同工酶 (CK MB)与对照组是否有差别来判断其对损伤心肌细胞的保护作用。方法 对 6 0例住院的冠心病患者于术前、术后 1h ,6h分别各测 1次CK MB。术前随机分为 2组 ,A组 30例 (术前不用 β 受体阻滞剂为对照组 ) ,B组 30例 (术前 1d开始口服倍他乐克普通片 ,每次 5 0mg ,每日 2次 ) ,通过两组酶学的差异来观察 β 受体阻滞剂的疗效。 结果 A组病人术后有12例CK MB数值高于正常范围 ,而B组病人中只有 1例CK MB升高 (P <0 0 5 )。术前 2组病人CK MB无差异 ,术后 1h及 6h两组相比较差异均有显著性 (P值分别为 0 0 12和 0 0 0 2 ) ;在对照组中 ,介入后 1h、6h与术前相比差异均有显著性 (P 值分别为 0 0 33和 0 2 2 )。住院期间 2组病人均无严重冠脉事件发生。结论 经皮冠状动脉介入治疗 (PCI)术前口服 β 受体阻滞剂可明显降低病人术后心肌酶升高的发生率 ,从而降低病人远期的心脏性死亡。
OBJECTIVE: To investigate whether β-blocker (CK) and serum CK-MB (CK-MB) in the intervention group were compared with those in the control group to determine their protective effects on injured cardiomyocytes. Methods CK MB was measured in 60 patients with coronary heart disease in preoperative, 1 hour and 6 hours after operation. Preoperative randomized into two groups, A group of 30 patients (preoperative β-blocker without the control group), B group of 30 patients (preoperative 1d oral beta metollole tablets, each 50mg, each Day 2 times), through the two groups of enzymatic differences to observe the efficacy of β-blockers. Results In group A, CK MB in 12 patients was higher than that in normal range, while in group B only 1 CK CK was increased (P <0.05). There was no significant difference in CK MB between the two groups before operation, and there was significant difference between the two groups at 1h and 6h after surgery (P values were 0 0 12 and 0 0 0 2 respectively). In the control group, 1h, 6h There were significant differences between before and after surgery (P values were 0 0 33 and 0 2 2, respectively). No serious coronary events occurred in both groups during hospitalization. Conclusion Percutaneous coronary intervention (PCI) before oral administration of beta-blockers can significantly reduce the incidence of postoperative myocardial enzymes, thereby reducing the long-term cardiac death in patients.